NCT00069160View on ClinicalTrials.gov

Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

September 30, 2003

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Lung NeoplasmsOvarian NeoplasmsCervix NeoplasmsRenal Neoplasms
Interventions
DRUG

docetaxel

Patients receive docetaxel intravenous (IV) over 1 hour on days 1 and 8.

DRUG

tariquidar

Patients receive tariquidar intravenous (IV) over 30 minutes on days 8 and 22.

OTHER

99mTc-sestamibi imaging

Bolus injection of 29 mCi of 99mTc-sestamibi intravenously for each imaging study.

Trial Locations (1)

20892

National Institutes of Health, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00069160 - Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer | Biotech Hunter | Biotech Hunter